However, the finding that promoting glucose metabolism in FUS and TDP-43 proteinopathies ameliorates disease phenotypes indicates that glucose metabolism could be a driver of FTD pathophysiology and therefore could become a promising therapeutic target. This evidence concerns the gene FUS and proteostasis deficiencies.